Professor Ben van Hout
Population Health, School of Medicine and Population Health
Emeritus Professor of Health Economics
b.a.vanhout@sheffield.ac.uk
+44 114 222 0827
+44 114 222 0827
+44 114 222 0749
(Fax)
Regent Court (ScHARR)
Full contact details
Professor Ben van Hout
Population Health, School of Medicine and Population Health
Regent Court (ScHARR)
30 Regent Street
Sheffield
S1 4DA
Population Health, School of Medicine and Population Health
Regent Court (ScHARR)
30 Regent Street
Sheffield
S1 4DA
- Profile
-
I joined ScHARR in November 2009 as Professor of Health Economics.
I have extensive experience in modelling and have contributed to the methodology of economic evaluation in various areas. In 1993 I was one of the earliest researchers to apply discrete event models and was the first to apply a non-parametric method to estimate costs in the presence of censoring. In 1994 I was the first to apply Fieller's approach to calculate confidence intervals around cost-effectiveness ratios, and I introduced the acceptability curve, which is now a well-known concept in cost-effectiveness analysis. In 1996 I was one of the first to apply probabilistic sensitivity analysis. In 2000 I was one of the initial people to explore Bayesian techniques in economic evaluation. I have had work published on discounting and estimating utility functions.
I am one of the founding members of the EuroQol group and I currently enjoy chairing the valuation task force within the EQ-5D group. My experience covers several therapeutic areas, including renal disease, cancer, osteoporosis, sepsis, schizophrenia, blood safety and most notably cardiovascular disease. My main interest concerns the use of elegant techniques, mostly to solve practical problems, but sometimes also because of the elegance itself.
- Publications
-
Show: Featured publications All publications
Featured publications
Journal articles
- Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States. Clinical Cardiology, 39(6), 313-320. View this article in WRRO
- Cost-effectiveness Analysis of Rivaroxaban in the Secondary Prevention of Acute Coronary Syndromes in Sweden. Cardiology and Therapy, 4(2), 131-153. View this article in WRRO
- Modelling the cost-effectiveness of combination therapy for early, rapidly progressing rheumatoid arthritis by simulating the reversible and irreversible effects of the disease. BMJ Open, 5(6). View this article in WRRO
- The Continuing Story of the Cost-Effectiveness of Photoselective Vaporization of the Prostate versus Transuretheral Resection of the Prostate for the Treatment of Symptomatic Benign Prostatic Obstruction. Value in Health, 18(4), 376-386.
- A Comparison of Methods for Converting DCE Values onto the Full Health-Dead QALY Scale. Medical Decision Making, 35(3), 328-340. View this article in WRRO
- Interim EQ-5D-5L Value Set for Poland: First Crosswalk Value Set in Central and Eastern Europe. Value in Health Regional Issues, 4, 19-23.
- Multinational Evidence of the Applicability and Robustness of Discrete Choice Modeling for Deriving EQ-5D-5L Health-State Values. Medical Care, 52(11), 935-943. View this article in WRRO
- Predicting preference-based utility values using partial proportional odds models.. BMC Res Notes, 7, 438. View this article in WRRO
- Assessing uncertainties surrounding combined endpoints for use in economic models.. Med Decis Making, 34(3), 300-310.
- Developing an EQ-5D-5L value set for England. QUALITY OF LIFE RESEARCH, 22.
All publications
Journal articles
- 691 - Understanding patient and physician preferences when choosing between biologic and oral systemic treatment options for moderate-to-severe atopic dermatitis: a discrete choice experiment. British Journal of Dermatology, 191(Supplement_2).
- Exploring health preference heterogeneity in the UK: Using the online elicitation of personal utility functions approach to construct EQ‐5D‐5L value functions on societal, group and individual level. Health Economics. View this article in WRRO
- Using the Online Elicitation of Personal Utility Functions Approach to Derive a Patient-Based 5-Level Version of EQ-5D Value Set: A Study in 122 Patients With Rheumatic Diseases From Germany. Value in Health, 27(3), 376-382.
- Using age-specific values for pediatric HRQoL in cost-effectiveness analysis: is there a problem to be solved? If so, how?. PharmacoEconomics, 41(10), 1165-1174. View this article in WRRO
- Hypothetical versus experienced health state valuation: a qualitative study of adult general public views and preferences. Quality of Life Research, 32(4), 1187-1197.
- The Online Elicitation of Personal Utility Functions (OPUF) tool: a new method for valuing health states [version 1; peer review: 1 approved]. Wellcome Open Research, 7. View this article in WRRO
- An innovative approach to modelling the optimal treatment sequence for patients with relapsing–remitting multiple sclerosis : implementation, validation, and impact of the decision-making approach. Advances in Therapy, 39(2), 892-908. View this article in WRRO
- Cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden. European Heart Journal - Quality of Care and Clinical Outcomes, 8(1), 31-38.
- Mapping EQ-5D-3L to EQ-5D-5L. Value in Health, 24(9), 1285-1293.
- Critical appraisal and issues regarding generalisability of comparative effectiveness studies of NOACs in atrial fibrillation and their relation to clinical trial data: a systematic review. BMJ Open, 11(2). View this article in WRRO
- Mortality prediction of the CHA2DS2-VASc score, the HAS-BLED score, and their combination in anticoagulated patients with atrial fibrillation. Journal of Clinical Medicine, 9(12).
- Cost-effectiveness of evolocumab in patients with familial hypercholesterolemia in Belgium. Atherosclerosis, 315, e36-e36.
- What potential risk reduction could be achieved with evolocumab treatment? A simulation based on observational data from a cohort of users in 10 European countries. European Heart Journal, 41(Supplement_2).
- Does Evolocumab use in Europe match 2019 ESC/EAS lipid guidelines? Results from the HEYMANS study. European Heart Journal, 41(Supplement_2).
- Additive predictive power of the CHA2DS2-VASc and HAS-BLED scores for mortality in patients with atrial fibrillation. European Heart Journal, 41(Supplement_2).
- Impact of patient characteristics on treatment outcomes in symptomatic venous thromboembolism: Results of HOKUSAI-VTE randomized trial analysis. TH Open, 04(03), e245-e254.
- The EQ-5D-5L value set for England : response to the “Quality Assurance”. Value in Health. View this article in WRRO
- Methodology of a novel risk stratification algorithm for patients with multiple myeloma in the relapsed setting. Oncology and Therapy, 7(2), 141-157. View this article in WRRO
- Updated cost-effectiveness analysis of evolocumab in patients with very high-risk atherosclerotic cardiovascular disease. JAMA Cardiology. View this article in WRRO
- Health-related quality of life and mortality in patients with pulmonary embolism: a prospective cohort study in seven European countries.. Quality of Life Research. View this article in WRRO
- Comparison of quality of life measurements: EQ-5D-5L versus disease/treatment-specific measures in pulmonary embolism and deep vein thrombosis. Quality of Life Research, 28(5), 1155-1177.
- Overview, update, and lessons learned from the international EQ-5D-5L valuation work: version 2 of the EQ-5D-5L valuation protocol. Value in Health, 22(1), 23-30. View this article in WRRO
- Pulmonary embolism in Europe - Burden of illness in relationship to healthcare resource utilization and return to work. Thrombosis Research, 170, 181-191. View this article in WRRO
- Deep-vein thrombosis in Europe — Burden of illness in relationship to healthcare resource utilization and return to work. Thrombosis Research, 170, 165-174. View this article in WRRO
- A new method for valuing health: directly eliciting personal utility functions. The European Journal of Health Economics. View this article in WRRO
- An exploration of the non‐iterative time trade‐off method to value health states. Health Economics, 27(8), 1247-1263. View this article in WRRO
- Correction to: Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets. PharmacoEconomics, 36(6), 727-727.
- Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets. PharmacoEconomics, 1-15. View this article in WRRO
- Valuing health‐related quality of life: An EQ‐5D‐5L value set for England. Health Economics, 27(1), 7-22. View this article in WRRO
- Cost-effectiveness of edoxaban compared to warfarin for the treatment and secondary prevention of venous thromboembolism in the UK. Journal of Market Access & Health Policy, 6(1), 1495974-1495974. View this article in WRRO
- New methods for modelling EQ-5D-5L value sets: An application to English data. Health Economics, 27(1), 23-38. View this article in WRRO
- INTERNATIONAL REGULATIONS AND RECOMMENDATIONS FOR UTILITY DATA FOR HEALTH TECHNOLOGY ASSESSMENT. PharmacoEconomics, 35(Suppl 1), 11-19. View this article in WRRO
- Sourcing and using appropriate health state utility values in economic models in health care. PharmacoEconomics, 35(Suppl 1), 7-9. View this article in WRRO
- Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease. JAMA Cardiology. View this article in WRRO
- The Importance of Economic Perspective and Quantitative Approaches in Oncology Value Frameworks of Drug Selection and Shared Decision Making. Journal of Managed Care & Specialty Pharmacy, 23(6-a Suppl), S6-S12. View this article in WRRO
- Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain. Clinical Therapeutics, 39(4), 771-786.e3. View this article in WRRO
- Cost-effectiveness of ocriplasmin for the treatment of vitreomacular traction and macular hole. Journal of Market Access & Health Policy, 4(1). View this article in WRRO
- Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States. Clinical Cardiology, 39(6), 313-320. View this article in WRRO
- Cost-effectiveness Analysis of Rivaroxaban in the Secondary Prevention of Acute Coronary Syndromes in Sweden. Cardiology and Therapy, 4(2), 131-153. View this article in WRRO
- Abstract 18114: Differences Between Observed and Predicted Cardiovascular Event Rates Using the Framingham and REACH Equations: The Case of High-intensity Statin Users in the United Kingdom. Circulation, 132(suppl_3).
- Modelling the cost-effectiveness of combination therapy for early, rapidly progressing rheumatoid arthritis by simulating the reversible and irreversible effects of the disease. BMJ Open, 5(6). View this article in WRRO
- The Continuing Story of the Cost-Effectiveness of Photoselective Vaporization of the Prostate versus Transuretheral Resection of the Prostate for the Treatment of Symptomatic Benign Prostatic Obstruction. Value in Health, 18(4), 376-386.
- A Comparison of Methods for Converting DCE Values onto the Full Health-Dead QALY Scale. Medical Decision Making, 35(3), 328-340. View this article in WRRO
- Interim EQ-5D-5L Value Set for Poland: First Crosswalk Value Set in Central and Eastern Europe. Value in Health Regional Issues, 4, 19-23.
- Multinational Evidence of the Applicability and Robustness of Discrete Choice Modeling for Deriving EQ-5D-5L Health-State Values. Medical Care, 52(11), 935-943. View this article in WRRO
- Predicting preference-based utility values using partial proportional odds models.. BMC Res Notes, 7, 438. View this article in WRRO
- A program of methodological research to arrive at the new international EQ-5D-5L valuation protocol.. Value Health, 17(4), 445-453.
- Assessing uncertainties surrounding combined endpoints for use in economic models.. Med Decis Making, 34(3), 300-310.
- Eliciting health state utilities for Dupuytren's contracture using a discrete choice experiment.. Acta Orthop, 84(6), 571-578. View this article in WRRO
- Extrapolating Survival in a Heterogeneous Patient Population with Metastatic Melanoma; A Case Study of Integrating Statistical and Clinical Consideration. Value in Health, 16(7), A594-A594.
- Disentangling Effects on Fatal and Non-Fatal Cardiovascular Events Over Time. Value in Health, 16(7), A590-A590.
- Developing an EQ-5D-5L value set for England. QUALITY OF LIFE RESEARCH, 22.
- A comparison of alternative variants of the lead and lag time TTO. Health Economics (United Kingdom), 22(5), 517-532.
- Evidence from four countries on the validity of the discrete choice model in quantifying health-states for the new EQ-5D-5L. QUALITY OF LIFE RESEARCH, 21, 12-12.
- Estimating Preference-Based EQ-5D Health State Utilities or Item Responses from Neuropathic Pain Scores. The Patient: Patient-Centered Outcomes Research, 5(3), 185-197.
- Estimating preference-based EQ-5D health state utilities or item responses from neuropathic pain scores.. Patient, 5(3), 185-197.
- Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets.. Value Health, 15(5), 708-715.
- PMS91 Using Discrete Choice Experiments (DCE) to Estimate Preference-Based Utilities for Dupuytren's Contracture (DC). Value in Health, 15(4), A50-A50.
- Quality of Life After PCI With Drug-Eluting Stents in Coronary Artery Bypass Surgery. Survey of Anesthesiology, 56(1), 6-6.
- Estimating preference-based single index measures for dementia using DEMQOL and DEMQOL-proxy. Value in Health, 15(2), 346-356.
- Cost-effectiveness of additional blood screening tests in the Netherlands. Transfusion, 52(3), 478-488.
- Cost-effectiveness of additional blood screening tests in the Netherlands.. Transfusion, 52(3), 478-488.
- Economic outcomes of percutaneous coronary intervention with drug-eluting stents versus bypass surgery for patients with left main or three-vessel coronary artery disease: one-year results from the SYNTAX trial.. Catheter Cardiovasc Interv, 79(2), 198-209.
- Mapping of the Insomnia Severity Index and other sleep measures to EuroQol EQ-5D health state utilities.. Health Qual Life Outcomes, 9, 119. View this article in WRRO
- Quality of life after PCI with drug-eluting stents or coronary-artery bypass surgery.. N Engl J Med, 364(11), 1016-1026.
- Cross-sectional study into the costs and impact on family functioning of 4-year-old children with aggressive behavior.. Prev Sci, 12(2), 192-200. View this article in WRRO
- A modeling approach to evaluate long-term outcome of prophylactic and on demand treatment strategies for severe hemophilia A.. Haematologica, 96(5), 738-743.
- Safe blood transfusion: How much do we want to pay?. Blood Transfusion, 9(SUPPL. 1).
- Survival after transfusion in the Netherlands.. Vox Sang, 100(2), 196-203.
- PSY67 PREDICTING EQ-5D UTILITIES FROM NEUROPATHIC PAIN SCORES: COMPARING INDIRECT MAPPING OF PREDICTED ITEM RESPONSES WITH DIRECT MAPPING OF SCORES. Value in Health, 13(7), A472-A473.
- Quantifying cost-effectiveness of controlling nosocomial spread of antibiotic-resistant bacteria: the case of MRSA.. PLoS One, 5(7), e11562. View this article in WRRO
- Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden. Applied Health Economics and Health Policy, 8(4), 251-265.
- Comparative effectiveness of antibiotics for the treatment of MRSA complicated skin and soft tissue infections.. Curr Med Res Opin, 26(7), 1565-1578.
- Cost-effectiveness of clopidogrel in STEMI patients in the Netherlands: a model based on the CLARITY trial.. Curr Med Res Opin, 26(3), 641-651.
- The PROTON study: profiles of blood product transfusion recipients in the Netherlands.. Vox Sang, 99(1), 54-64.
- 059 Economic evaluation of the French subset of the SYNTAX trial at 1 year: drug-eluting stents compared with bypass surgery for patients with 3-vessel and/or left main coronary artery disease. Archives of Cardiovascular Diseases Supplements, 2(1), 20-20.
- Cost effectiveness of long-acting risperidone in Sweden.. Appl Health Econ Health Policy, 8(5), 327-341.
- Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations.. Appl Health Econ Health Policy, 8(4), 251-265.
- Economic evaluation of zoledronic acid for the prevention of osteoporotic fractures in postmenopausal women with early-stage breast cancer receiving aromatase inhibitors in the UK.. Ann Oncol, 21(7), 1529-1536.
- Economic Evaluation of Zoledronic Acid for the Prevention of Osteoporotic Fractures in Post-Menopausal Women with Early Breast Cancer Receiving Aromatase Inhibitors in the United Kingdom.. Poster Session Abstracts.
- MO12 COMPARISON OF THREE META-MODELS FOR UNCERTAINTY ANALYSIS. Value in Health, 12(7), A235-A235.
- Monitoring viral incidence rates: tools for the implementation of European Union regulations.. Vox Sang, 96(4), 298-308.
- Efficacy of recombinant activated factor VII vs. activated prothrombin complex concentrate for patients suffering from haemophilia complicated with inhibitors: a Bayesian meta-regression.. Haemophilia, 15(2), 420-436.
- A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss.. BMC Health Serv Res, 9, 32. View this article in WRRO
- Cost-effectiveness of additional hepatitis B virus nucleic acid testing of individual donations or minipools of six donations in the Netherlands.. Transfusion, 49(2), 311-319.
- Clinical benefits of rivaroxaban for VTE prevention after elective hip or knee replacement surgery. EJHP Practice, 15(3), 34-36.
- Economic evaluation of zoledronic acid for the prevention of osteoporotic fractures in post-menopausal women with early-stage breast cancer receiving aromatase inhibitors in the United Kingdom. European Journal of Cancer Supplements, 6(7), 69-70.
- The cost-effectiveness of atypicals in the UK.. Value Health, 11(7), 1007-1021.
- PIN2 ASSESSING ANTIMICROBIAL SUCCESS RATES IN THE TREATMENT OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) COMPLICATED SKIN AND SOFT TISSUE INFECTIONS (CSSTI):A BAYESIAN META-ANALYSIS. Value in Health, 11(6), A428-A428.
- Transcatheter valve implantation for patients with aortic stenosis: a position statement from the European association of cardio-thoracic surgery (EACTS) and the European Society of Cardiology (ESC), in collaboration with the European Association of Percutaneous Cardiovascular Interventions (EAPCI).. EuroIntervention, 4(2), 193-199.
- Transcatheter valve implantation for patients with aortic stenosis: a position statement from the European Association of Cardio-Thoracic Surgery (EACTS) and the European Society of Cardiology (ESC), in collaboration with the European Association of Percutaneous Cardiovascular Interventions (EAPCI).. Eur J Cardiothorac Surg, 34(1), 1-8.
- Transcatheter valve implantation for patients with aortic stenosis: a position statement from the European Association of Cardio-Thoracic Surgery (EACTS) and the European Society of Cardiology (ESC), in collaboration with the European Association of Percutaneous Cardiovascular Interventions (EAPCI).. Eur Heart J, 29(11), 1463-1470.
- Clinical practice guideline for cardiovascular risk management in the Netherlands.. Neth J Med, 66(4), 169-174.
- Recommendations for reporting economic evaluations of haemophilia prophylaxis: a nominal groups consensus statement on behalf of the Economics Expert Working Group of The International Prophylaxis Study Group (vol 14, pg 127, 2008). HAEMOPHILIA, 14(2), 414-414.
- Assessing performance of a randomized versus a non-randomized study design.. Contemp Clin Trials, 29(2), 293-303.
- 98 – Health-economic analysis of risperidone long-acting injectable compared to olanzapine and a conventional depot in Sweden and Finland. Schizophrenia Research, 98, 73-74.
- Cost-effectiveness and budget impact of long-acting risperidone in Portugal: a modeling exercise.. Curr Med Res Opin, 24(2), 349-358.
- Modelling approaches: the case of schizophrenia.. Pharmacoeconomics, 26(8), 633-648.
- Recommendations for reporting economic evaluations of haemophilia prophylaxis: a nominal groups consensus statement on behalf of the Economics Expert Working Group of The International Prophylaxis Study Group.. Haemophilia, 14(1), 127-132.
- A probabilistic model for analyzing viral risks of plasma-derived medicinal products.. Transfusion, 48(1), 153-162.
- Oral Antiplatelet Therapy in Secondary Prevention of Cardiovascular Events. PharmacoEconomics, 25(12), 1063-1082.
- Efficacy of Recombinant Activated Factor VII (rFVIIa) vs. Activated Prothrombin Complex Concentrate (APCC) in Patients with Hemophilia with Inhibitors: A Bayesian Meta-Analysis.. Blood, 110(11), 3964-3964.
- PCN11 COST-UTILITY ANALYSIS OF DASATINIB IN PATIENTS AFTER FIRST-LINE FAILURE OF IMATINIB IN CHRONIC MYELOID LEUKEMIA (CML) IN AUSTRIA. Value in Health, 10(6), A325-A325.
- PMH24 THE COST EFFECTIVENESS OF PALIPERIDONE EXTENDED-RELEASE OROS IN SWEDEN, FINLAND, DENMARK AND NORWAY. Value in Health, 10(6), A294-A295.
- PMH22 A PHARMACOECONOMIC ANALYSIS OF COMPLIANCE GAINS ON ANTIPSYCHOTIC MEDICATIONS. Value in Health, 10(6), A294-A294.
- Cost effectiveness of epidural injection of steroids and local anesthetics for relief of zoster-associated pain.. Anesthesiology, 107(4), 678-679.
- Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom.. Rheumatology (Oxford), 46(8), 1320-1328.
- Oral antiplatelet therapy in secondary prevention of cardiovascular events: an assessment from the payer's perspective.. Pharmacoeconomics, 25(12), 1063-1082.
- Long-term clopidogrel therapy in patients receiving percutaneous coronary intervention.. Pharmacoeconomics, 25(9), 769-782.
- Cost-effectiveness of the unrestricted use of sirolimus-eluting stents vs. bare metal stents at 1 and 2-year follow-up: results from the RESEARCH Registry.. Eur Heart J, 27(24), 2996-3003.
- [Cost-effectiveness of clopidogrel vs. aspirin treatment in high-risk acute coronary syndrome patients in Denmark].. Ugeskr Laeger, 168(35), 2911-2915.
- Costs and benefits of bacterial culturing and pathogen reduction in the Netherlands.. Transfusion, 46(6), 956-965.
- The use of a surgical sealant (CoSeal) in cardiac and vascular reconstructive surgery: an economic analysis.. J Cardiovasc Surg (Torino), 47(2), 161-170.
- Cost-effectiveness of clopidogrel vs. aspirin treatment in high-risk acute coronary syndrome patients in Denmark. Ugeskrift for Laeger, 168(35), 2911-2915.
- PCV90 COST EFFECTIVENESS OF FONDAPARINUX COMPARED WITH ENOXAPARIN FOR EXTENDED PROPHYLAXIS AGAINST VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING HIP FRACTURE SURGERY USING DUTCH ESTIMATES OF COSTS. Value in Health, 8(6), A116-A116.
- PCV91 COST EFFECTIVENESS OF EXTENDED PROPHYLAXIS WITH FONDAPARINUX TO PREVENT VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING HIP FRACTURE SURGERY USING UK AND DUTCH ESTIMATES OF COSTS. Value in Health, 8(6), A116-A116.
- Costs and effects of long-acting risperidone in comparison to oral atypical and conventional depot formulations for the treatment of patients with schizophrenia in Germany. PSYCHOPHARMAKOTHERAP, 12(5), 183-192.
- Optimal allocation of resources over health care programmes: dealing with decreasing marginal utility and uncertainty. HEALTH ECON, 14(7), 655-667.
- One year cost effectiveness of sirolimus eluting stents compared with bare metal stents in the treatment of single native de novo coronary lesions: an analysis from the RAVEL trial.. Heart, 91(4), 507-512.
- Clinical effectiveness of influenza vaccination in persons younger than 65 years with high-risk medical conditions: the PRISMA study.. Arch Intern Med, 165(3), 274-280.
- Costs and effects of long-acting risperidone in comparison to oral atypical and conventional depot formulations for the treatment of patients with schizophrenia in Germany. Psychopharmakotherapie, 12(5), 183-192.
- Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.. Pharmacoeconomics, 23 Suppl 1, 49-61.
- Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada.. Pharmacoeconomics, 23 Suppl 1, 62-74.
- Modelling the treated course of schizophrenia: development of a discrete event simulation model.. Pharmacoeconomics, 23 Suppl 1, 17-33.
- Dynamic microsimulation to model multiple outcomes in cohorts of critically ill patients. INTENS CARE MED, 30(12), 2237-2244.
- Sirolimus eluting stent implantation for patients with multivessel disease: rationale for the Arterial Revascularisation Therapies Study part II (ARTS II).. Heart, 90(9), 995-998.
- Prevalence and incidence of severe sepsis in Dutch intensive care units.. Crit Care, 8(4), R153-R162. View this article in WRRO
- [Sepsis, a complicated syndrome with major medical and social consequences].. Ned Tijdschr Geneeskd, 148(20), 975-978.
- Three-year outcome after coronary stenting versus bypass surgery for the treatment of multivessel disease.. Circulation, 109(9), 1114-1120.
- Sepsis, a complicated syndrome with major medical and social consequences. Nederlands Tijdschrift voor Geneeskunde, 148(20), 975-978.
- PMH10 COSTS AND EFFECTS OF RISPERDAL CONSTATM IN COMPARISON TO CONVENTIONAL DEPOT AND SHORT-ACTING ATYPICAL FORMULATIONS IN GERMANY. Value in Health, 6(6), 691-692.
- Cost-effectiveness of extending prophylaxis with fondaparinux in preventing venous thromboembolism following hip fracture surgery. VALUE HEALTH, 6(6), 652-652.
- Cost-effectiveness analysis of antithrombotic treatment with clopidogrel in patients with myocardial infarction, stroke, and peripheral arterial disease in the Netherlands. VALUE HEALTH, 6(6), 653-653.
- Quality of life and NYHA class 30 years after mechanical aortic valve replacement.. Cardiovasc Surg, 11(5), 381-387.
- 1052 Cost-effectiveness of epoetin alfa (EPO) and darbepoetin alfa (DARB) based on hematopoietic response rates and cost of therapy. European Journal of Cancer Supplements, 1(5), S313-S314.
- Meta-analysis: comparing the efficacy of proton pump inhibitors in short-term use.. Aliment Pharmacol Ther, 17(10), 1237-1245.
- Design of the Dutch prevention of influenza, surveillance and management (PRISMA) study.. Vaccine, 21(15), 1719-1724.
- A pharmacoeconomic comparison of the efficacy and costs of pantoprazole and omeprazole for the treatment of peptic ulcer or gastroesophageal reflux disease in The Netherlands.. Clin Ther, 25(2), 635-646.
- Direct stenting with the Bx VELOCITY balloon-expandable stent mounted on the Raptor rapid exchange delivery system versus predilatation in a European randomized Trial: the VELVET trial.. Int J Cardiovasc Intervent, 5(1), 17-26.
- Cost-utility analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer.. Pharmacoeconomics, 21(16), 1153-1169.
- Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis.. Crit Care Med, 31(1), 1-11.
- Prevention comes of age?. Eur J Epidemiol, 18(12), 1107-1108.
- Whom and how to treat: weighing the costs and effects.. Scand J Gastroenterol Suppl(239), 3-10.
- The cost effectiveness of two new antiepileptic therapies in the absence of direct comparative data: a first approximation.. Pharmacoeconomics, 21(5), 315-326.
- PIN1 THE COSTS OF SEVERE SEPSIS—THE NETHERLANDS, 2000. Value in Health, 5(6), 558-558.
- Screening for aneurysms after successful treatment for subarachnoid haemorrhage: Do we have the evidence?. VALUE HEALTH, 5(6), 493-494.
- Association between joint bleeds and pettersson scores in severe haemophilia. Acta Radiologica, 43(5), 528-532.
- Association between joint bleeds and Pettersson scores in severe haemophilia.. Acta Radiol, 43(5), 528-532.
- Costs and effectiveness of using coumarins before, during and after coronary angioplasty.. Pharmacoeconomics, 20(12), 847-853.
- Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis.. Pharmacoeconomics, 20(1), 1-7.
- Prophylaxis or on-demand? The costs and effects of treatment strategies including switches.. BLOOD, 98(11), 428A-429A.
- PCN4: COMPARING MEAN VERSUS MEDIAN SURVIVAL AS A PRELUDE TO COST-EFFECTIVENESS (C/E) ANALYSES. Value in Health, 4(2), 85-85.
- Cost-efficacy in interventional cardiology; results from the EPISTENT study. Evaluation of Platelet IIb/IIIa Inhibitor For Stenting Trial.. Eur Heart J, 22(16), 1476-1484.
- Cost-effectiveness of oral anticoagulants versus aspirin in patients after infrainguinal bypass grafting surgery.. J Vasc Surg, 34(2), 254-262.
- Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the Arterial Revascularization Therapy Study (ARTS) trial.. Circulation, 104(5), 533-538.
- Cost-effectiveness of HMG coenzyme reductase inhibitors; whom to treat?. Eur Heart J, 22(9), 751-761.
- Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease.. N Engl J Med, 344(15), 1117-1124.
- Costs of outpatient anticoagulant treatment in patients with cerebral and peripheral arterial occlusive disease. Thrombosis and Haemostasis, 85(1), 52-56.
- Small health benefit can be achieved with preventative postmenopausal hormone therapy in Dutch women. Nederlands Tijdschrift voor Geneeskunde, 145(19), 910-914.
- Costs in the last year of life in The Netherlands.. Inquiry, 38(1), 73-80.
- Randomized comparison of primary stenting and provisional balloon angioplasty guided by flow velocity measurement. Doppler Endpoints Balloon Angioplasty Trial Europe (DEBATE) II Study Group.. Circulation, 102(24), 2930-2937.
- Comparison of effectiveness and cost effectiveness of CABG versus percutaneous intervention in patients with multivessel disease by age. CIRCULATION, 102(18), 549-549.
- Quality of life after CABG and stented angioplasty: Results from the ARTS study. CIRCULATION, 102(18), 549-549.
- A Bayesian approach to economic analyses of clinical trials: the case of stenting versus balloon angioplasty.. Health Econ, 9(7), 599-609.
- Comparison of effectiveness and cost effectiveness of CABG versus percutaneous intervention in diabetic patients with multi vessel disease. EUR HEART J, 21, 222-222.
- Postmenopausal hormone therapy: less favourable risk-benefit ratios in healthy Dutch women.. J Intern Med, 248(2), 143-150.
- A fair approach to discounting future effects: taking a societal perspective.. J Health Serv Res Policy, 5(2), 114-118.
- Diabetes nephropathy in the Netherlands: a cost effectiveness analysis of national clinical guidelines.. Health Policy, 51(3), 135-147.
- The results of a randomized controlled trial evaluating TIPS and endoscopic therapy in cirrhotic patients with gastro-esophageal variceal bleeding. J HEPATOL, 32, 71-71.
- The results of a randomized controlled trial evaluating TIPS and endoscopic therapy in cirrhotic patients with gastro-esophageal variceal bleeding. European Journal of Gastroenterology & Hepatology, 11(12), A86-A86.
- The ARTS study (Arterial Revascularization Therapies Study).. Semin Interv Cardiol, 4(4), 209-219.
- Estimating parametric relationships between health description and health valuation with an application to the EuroQol EQ-5D.. J Health Econ, 18(5), 551-571.
- Economic evaluation in the field of cardiology: theory and practice.. Prog Cardiovasc Dis, 42(2), 167-173.
- An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectal cancer.. Anticancer Drugs, 10(3), 283-288.
- Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis.. Ther Drug Monit, 21(1), 63-73.
- The ARTS (Arterial Revascularization Therapies Study): Background, goals and methods. International Journal of Cardiovascular Interventions, 2(1), 41-50.
- Incremental cost of medical care after hip fracture and first vertebral fracture: the Rotterdam study.. Osteoporos Int, 10(1), 66-72.
- Discounting costs and effects: a reconsideration.. Health Econ, 7(7), 581-594.
- How should different life expectancies be valued? Diminishing marginal utility and discounting future effects have similar consequences.. BMJ, 317(7166), 1155.
- Hip fracture prediction in elderly men and women: validation in the Rotterdam study.. J Bone Miner Res, 13(10), 1587-1593.
- [Economic evaluation of cardiology; background and application].. Ned Tijdschr Geneeskd, 142(38), 2083-2086.
- [Guidelines and costs].. Ned Tijdschr Geneeskd, 142(38), 2075-2077.
- Determining costs and cost-effectiveness of epilepsy.. Am J Manag Care, 4(9 Suppl), S501-S509.
- Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet, 352(9129), 673-681.
- Sample size calculation in economic evaluations.. Health Econ, 7(4), 327-335.
- Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications.. Eur Heart J, 19 Suppl D, D59-D66.
- Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications.. Am Heart J, 135(4), S98-106.
- Use of abciximab in interventional cardiology.. Eur Heart J, 19 Suppl D, D31-D39.
- Use of abciximab in interventional cardiology.. Am Heart J, 135(4), S67-S76.
- Costs and effects of stent implantation versus balloon angioplasty. Journal of the American College of Cardiology, 31, 50-50.
- Economic evaluation within cardiology; Background and application [4] (multiple letters). Nederlands Tijdschrift voor Geneeskunde, 142(39), 2164-2165.
- Economic evaluation in cardiology; background and application. Nederlands Tijdschrift voor Geneeskunde, 142(38), 2083-2086.
- Guidelines and costs. Nederlands Tijdschrift voor Geneeskunde, 142(38), 2075-2077.
- How should different life expectancies be valued?. BMJ, 317(7166), 1155.
- Coping with multiple morbidity in a life table.. Math Popul Stud, 7(1), 29-109.
- Economic evaluation of benazepril in chronic renal insufficiency.. Kidney Int Suppl, 63, S159-S162.
- Relationship between seizure frequency and costs and quality of life of outpatients with partial epilepsy in France, Germany, and the United Kingdom.. Epilepsia, 38(11), 1221-1226.
- Cost effectiveness of DNA diagnosis for four monogenic diseases.. J Med Genet, 34(9), 741-745.
- Bone density and risk of hip fracture in men and women: cross sectional analysis.. BMJ, 315(7102), 221-225.
- Modelling in economic evaluation: an unavoidable fact of life.. Health Econ, 6(3), 217-227.
- Current issues in the management of epilepsy: the impact of frequent seizures on cost of illness, quality of life, and mortality.. Epilepsia, 38 Suppl 1, S1-S8.
- Cost-Effectiveness of Perioperative Mupirocin Nasal Ointment in Cardiothoracic Surgery. Infection Control & Hospital Epidemiology, 17(12), 786-792.
- Cost effectiveness of stent implantation versus PTCA: the BENESTENT experience.. Semin Interv Cardiol, 1(4), 263-268.
- Simulation models in the planning of health care facilities: an application in the case of neonatal extracorporeal membrane oxygenation.. J Health Serv Res Policy, 1(4), 198-204.
- [Costs due to osteoporosis-induced fractures in The Netherlands; possibilities for cost control].. Ned Tijdschr Geneeskd, 140(33), 1684-1688.
- Economic aspects of treatment with captopril for patients with asymptomatic left ventricular dysfunction in The Netherlands.. Eur Heart J, 17(5), 731-740.
- The cost of osteoporosis related fractures in the netherlands. Osteoporosis International, 6(S1), 124-124.
- Cost-effectiveness of fracture prevention: Time of intervention. Osteoporosis International, 6(S1), 124-124.
- Costs of osteoporosis-related fractures in the Netherlands, 1993; possibilities of cost control. Nederlands Tijdschrift voor Geneeskunde, 140(33), 1684-1688.
- Cost benefit analysis of the Zwolle Infarction Study. Hart Bulletin, 27(4), 119-123.
- Cost-effectiveness of perioperative mupirocin nasal ointment in cardiothoracic surgery.. Infect Control Hosp Epidemiol, 17(12), 786-792.
- Costs and effects of c7E3 in high risk PTCA patients. An indirect analysis for The Netherlands.. Eur Heart J, 16 Suppl L, 81-85.
- A cost-effective analysis of primary coronary angioplasty versus thrombolysis for acute myocardial infarction.. Am J Cardiol, 76(11), 830-833.
- Costs and effects of long-term oral anticoagulant treatment after myocardial infarction.. JAMA, 273(12), 925-928.
- [Is the use of helicopters with a trauma team in severely injured accident victims in The Netherlands cost effective? A modelling approach].. Ned Tijdschr Geneeskd, 138(46), 2310-2315.
- Assessing the benefits of transplant services.. Baillieres Clin Gastroenterol, 8(3), 411-423.
- Costs, effects and C/E-ratios alongside a clinical trial.. Health Econ, 3(5), 309-319.
- Economic evaluation and the reimbursement of drugs: Current policies and future trends. European Journal of Clinical Research, 6, 186-194.
- Is use of helicopters with medical crews for seriously injured accident victims cost-effective in the Netherlands? A modelling approach. Nederlands Tijdschrift voor Geneeskunde, 138(46), 2310-2315.
- Cost-effectiveness of HA-1A treatment for patients with sepsis.. Prog Clin Biol Res, 388, 435-443.
- Effects of ACE inhibitors on heart failure in The Netherlands: a pharmacoeconomic model.. Pharmacoeconomics, 3(5), 387-397.
- Heart transplantation in the Netherlands; costs, effects and scenarios.. J Health Econ, 12(1), 73-93.
- [Cost-effectiveness analysis of human monoclonal antibody HA-1A in patients with sepsis syndrome].. Ned Tijdschr Geneeskd, 137(7), 360-364.
- Cost-effectiveness of treatment of patients with sepsis with HA-IA. Nederlands Tijdschrift voor Geneeskunde, 137(7), 360-364.
- EUROQOL(C) - A REPLY AND REMINDER. HEALTH POLICY, 20(3), 329-332.
- Deep vein thrombosis in Europe—health-related quality of life and mortality. Clinical and Applied Thrombosis/Hemostasis, 25. View this article in WRRO
Chapters
- Experimental Design for the Valuation of the EQ-5D-5L, Value Sets for EQ-5D-5L (pp. 29-54). Springer International Publishing
- Estimating a parametric relation between health description and health valuation using the EuroQol Instrument, EQ-5D concepts and methods: A developmental history (pp. 157-170). Springer Netherlands
- Some considerations concerning negative values for EQ-5D health states, EQ-5D concepts and methods: A developmental history (pp. 171-179). Springer Netherlands
- How should we Measure the Economic Consequences of Critical Illness?, Surviving Intensive Care (pp. 221-234). Springer Berlin Heidelberg
Conference proceedings papers
- RELATIONSHIPS BETWEEN HETEROTOPIC OSSIFICATION VOLUME AND FUNCTIONAL AND QUALITY OF LIFE ENDPOINTS IN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP). VALUE IN HEALTH, Vol. 26(6) (pp S28-S29)
- THE IMPACTS OF AGE AND GENDER ON MAPPED EQ-5D5L UTILITIES AND QUALITY-ADJUSTED LIFE YEARS (QALYS) IN CANCER CLINICAL TRIALS. VALUE IN HEALTH, Vol. 26(6) (pp S334-S334)
- COMPARING ALGORITHMS FOR MAPPING FROM EQ-5D-3L TO EQ-5D-5L IN TWO PATIENT COHORTS. VALUE IN HEALTH, Vol. 26(6) (pp S343-S344)
- RELATING HETEROTOPIC OSSIFICATION VOLUME TO JOINT FUNCTION AND QUALITY OF LIFE: A SIMULATION STUDY IN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP). VALUE IN HEALTH, Vol. 26(6) (pp S288-S288)
- RWD5 Using Linked Databases to Explore Resource Use and Real-World Outcomes in a Rare Disease: Pompe Disease in England. Value in Health, Vol. 25(12) (pp S448-S448)
- PCR279 Value-Based Assessment of Clinical Trial Outcomes: A Hypothetical Example Using the Childhood Autism Rating Scale in Autism Spectrum Disorder. Value in Health, Vol. 25(12) (pp S444-S444)
- PCR166 Online Elicitation of Personal Utility Functions (OPUF) – An Open, Modular Health Valuation Platform. Value in Health, Vol. 25(12) (pp S423-S423)
- PCR28 The OPUF Tool: A New Type of Online Survey for Creating Value Sets for the EQ-5D-5L on the Societal-, Group-, and Individual Person Level. Value in Health, Vol. 25(7) (pp S546-S546)
- 85:oral The EQ-5D-5L OPUF survey: quantifying health priorities on the individual person level using compositional preference elicitation techniques. Abstracts
- THE OPUF TOOL: A NEW TYPE OF ONLINE SURVEY FOR CREATING VALUE SETS FOR THE EQ-5D-5L ON THE SOCIETAL-, GROUP-, AND INDIVIDUAL PERSON LEVEL. VALUE IN HEALTH, Vol. 25(7) (pp S546-S546)
- A NEW ONLINE TOOL FOR VALUING HEALTH STATES: ELICITING PERSONAL UTILITY FUNCTIONS FOR THE EQ-5D-5L. VALUE IN HEALTH, Vol. 25(1) (pp S13-S13)
- Online Elicitation of Personal Utility Functions (OPUF): An Open, Modular Health Valuation Platform. PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, Vol. 15(6) (pp 734-734)
- The Online elicitation of Personal Utility Functions (OPUF) Tool: a new method to construct (patient) preferences for small groups and on the individual level. QUALITY OF LIFE RESEARCH, Vol. 31 (pp S9-S10)
- ONLINE ELICITATION OF PERSONAL UTILITY FUNCTIONS (OPUF) AN OPEN, MODULAR HEALTH VALUATION PLATFORM. VALUE IN HEALTH, Vol. 25(12) (pp S423-S423)
- VALUE-BASED ASSESSMENT OF CLINICAL TRIAL OUTCOMES: A HYPOTHETICAL EXAMPLE USING THE CHILDHOOD AUTISM RATING SCALE IN AUTISM SPECTRUM DISORDER. VALUE IN HEALTH, Vol. 25(12) (pp S444-S444)
- USING LINKED DATABASES TO EXPLORE RESOURCE USE AND REAL-WORLD OUTCOMES IN A RARE DISEASE: POMPE DISEASE IN ENGLAND. VALUE IN HEALTH, Vol. 25(12) (pp S448-S448)
- Preference Study in Childhood Autism Spectrum Disorder (ASD) using the Childhood Autism Rating Scale (CARS2): A Feasibility Assessment. QUALITY OF LIFE RESEARCH, Vol. 30(SUPPL 1) (pp S113-S114)
- FAIR INTERPERSONAL UTILITY COMPARISON IN THE CONTEXT OF HEALTH VALUATION: DESCRIPTION AND FIRST EMPIRICAL EVALUATION OF A NEW MULTI-STEP PREFERENCE AGGREGATION PROCEDURE. MEDICAL DECISION MAKING, Vol. 40(5) (pp E407-E408)
- Additive predictive power of the cha2ds2-vasc and has-bled scores for mortality in patients with atrial fibrillation. EUROPEAN HEART JOURNAL SUPPLEMENTS, Vol. 22(N) (pp N10-N10)
- PCV40 COST-EFFECTIVENESS OF EVOLOCUMAB IN ATHEROSCLEROTIC CARDIOVASCULAR DISEASE PATIENTS WITH VARYING RISK PROFILES IN SWEDEN. Value in Health, Vol. 22 (pp S548-S548)
- P1225Cost-effectiveness of evolocumab in patients with high atherosclerotic cardiovascular risk in Sweden. European Heart Journal, Vol. 40(Supplement_1)
- P654Effectiveness of evolocumab for patients with familial hypercholesteraemia (FH) in European clinical practice. European Heart Journal, Vol. 40(Supplement_1)
- TWO-YEAR SURVIVAL WITH AXICABTAGENE CILOLEUCEL IN RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA: AN UPDATED ANALYSIS. HemaSphere, Vol. 3 (pp 817-817)
- An updated cost-effectiveness analysis of evolocumab therapy for reducing cardiovascular events in very high-risk patients with atherosclerotic cardiovascular disease according to the 2018 ACC/AHA guideline. Journal of Clinical Lipidology, Vol. 13(3) (pp e31-e31)
- MS2 AN UPDATED TWO-YEAR SURVIVAL ANALYSIS OF AXICABTAGENE CILOLEUCEL (AXI-CEL) IN RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA (R/R-LBCL). Value in Health, Vol. 22 (pp S41-S41)
- Additive predictive power of the CHA2DS2-VASc and has bled scores for mortality in patients with atrial fibrillation. EUROPEAN HEART JOURNAL SUPPLEMENTS, Vol. 21(J) (pp J23-J23)
- Effectiveness of evolocumab for patients with familial hypercholesteraemia (FH) in European clinical practice. EUROPEAN HEART JOURNAL, Vol. 40 (pp 263-263)
- Cost-effectiveness of evolocumab in patients with high atherosclerotic cardiovascular risk in Sweden. EUROPEAN HEART JOURNAL, Vol. 40 (pp 681-681)
- COST-EFFECTIVENESS OF EVOLOCUMAB IN ATHEROSCLEROTIC CARDIOVASCULAR DISEASE PATIENTS WITH VARYING RISK PROFILES IN SWEDEN. VALUE IN HEALTH, Vol. 22 (pp S548-S548)
- P1699Characteristics of patients prescribed Evolocumab in Europe. Does clinical use match clinical guidelines?. European Heart Journal, Vol. 39(suppl_1)
- The impact of co-morbidity on the disease burden of VTE. Journal of Thrombosis and Thrombolysis, Vol. 46(4) (pp 507-515)
- The Impact Of Co-Morbidity On The Disease Burden Of VTE. Value in Health, Vol. 20(9) (pp A601-A601)
- The Comparison of EQ-5D-5L Versus Disease/Treatment-Specific Measures in Pulmonary Embolism and Deep Vein Thrombosis. Value in Health, Vol. 20(9) (pp A623-A623)
- Burden Of Illness Of Deep-Vein Thrombosis In Europe – Healthcare Resource Utilization And Productivity Loss. Value in Health, Vol. 20(9) (pp A612-A612)
- OBSERVED VERSUS PREDICTED CARDIOVASCULAR EVENT RATES IN PRIMARY PREVENTION DIABETIC PATIENTS RECEIVING HIGH-INTENSITY STATINS IN THE UNITED KINGDOM. Journal of the American College of Cardiology, Vol. 69(11) (pp 1852-1852)
- BURDEN OF ILLNESS OF DEEP VEIN THROMBOSIS IN EUROPE - MORTALITY AND HEALTH RELATED QUALITY OF LIFE. VALUE IN HEALTH, Vol. 20(9) (pp A611-A611)
- BURDEN OF ILLNESS OF PULMONARY EMBOLISM IN EUROPE - MORTALITY AND HEALTH RELATED QUALITY OF LIFE. VALUE IN HEALTH, Vol. 20(9) (pp A611-A611)
- BURDEN OF ILLNESS OF PULMONARY EMBOLISM IN EUROPE - HEALTHCARE RESOURCE UTILIZATION AND PRODUCTIVITY LOSS. VALUE IN HEALTH, Vol. 20(9) (pp A611-A611)
- Cost-Effectiveness of Evolocumab in Patients with High Cardiovascular Risk in Spain. Value in Health, Vol. 19(7) (pp A651-A652)
- The Economic Burden of Pulmonary Embolism in Europe. Value in Health, Vol. 19(7) (pp A365-A365)
- Cost-Effectiveness of Edoxaban Compared to Warfarin for The Treatment and Secondary Prevention of Venous Thromboembolism in The UK. Value in Health, Vol. 19(7) (pp A653-A654)
- An Analysis of the Efficacy and Safety of Edoxaban in Comparison with Rivaroxaban in the Treatment of Deep Vein Thrombosis and Pulmonary Embolism. Value in Health, Vol. 19(7) (pp A637-A638)
- Directly Eliciting Personal Utility Functions From A Convenience Sample Of 30 Health Outcomes Professionals: A Pilot Study. Value in Health, Vol. 19(7) (pp A473-A473)
- Adjustment Of OS In Crystal For Post-Study Anti-Cancer Therapies. Value in Health, Vol. 19(7) (pp A394-A394)
- Cost-Effectiveness of LDL-C Lowering With Evolocumab In Patients With High Cardiovascular Risk In The United States. Value in Health, Vol. 19(3) (pp A3-A3)
- Directly Eliciting Personal Utility Functions: A New Way To Value Health-Related Quality Of Life. Value in Health, Vol. 18(3) (pp A37-A37)
- Deterministic Versus Stochastic Prediction of Risk for Cardiovascular Events. Value in Health, Vol. 17(7) (pp A558-A558)
- 129 Cost effectiveness of XPS vs TURP, a UK analysis. European Urology Supplements, Vol. 13(1) (pp e129-e129)
- Cost-Effectiveness Analysis of Rivaroxaban in Secondary Prevention of ACS in Sweden. Value in Health, Vol. 16(7) (pp A524-A524)
- MULTINATIONAL CONSISTENCY OF A DISCRETE CHOICE MODEL IN QUANTIFYING HEALTH STATES FOR THE EXTENDED 5-LEVEL EQ-5D. VALUE IN HEALTH, Vol. 16(7) (pp A326-A326)
- The use and impact of value of information analysis in decision-making.. Value Health, Vol. 16(3) (pp A30). United States
- HEALTH CARE RESOURCE UTILIZATION (HCRU) AND COSTS AMONG PATIENTS TREATED FOR NOSOCOMIAL PNEUMONIA (NP) CAUSED BY METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS (MRSA): SECONDARY ANALYSIS OF A MULTI-CENTER RANDOMIZED CONTROLLED STUDY. VALUE IN HEALTH, Vol. 15(4) (pp A10-A10)
- COMBINING DCE AND TTO INTO A SINGLE VALUE FUNCTION. VALUE IN HEALTH, Vol. 14(7) (pp A238-A239)
- THE POWER OF ASSUMPTIONS. VALUE IN HEALTH, Vol. 14(7) (pp A235-A235)
- A CONCEPTUAL FRAMEWORK THAT CAPTURES THE MULTIDIMENSIONAL ASPECT OF ADHERENCE IN A HEALTH-ECONOMIC MODEL: AN APPLICATION IN CHRONIC NONMALIGNANT PAIN MANAGEMENT. VALUE HEALTH, Vol. 13(7) (pp A242-A243)
- COST-EFFECTIVENESS OF ATORVASTATIN IN ACUTE CORONARY SYNDROME PATIENTS IN SWEDEN. VALUE IN HEALTH, Vol. 13(3) (pp A166-A167)
- COST-EFFECTIVENESS OF ATORVASTATIN IN ACUTE CORONARY SYNDROME (ACS) PATIENTS IN SPAIN. VALUE HEALTH, Vol. 13(3) (pp A165-A166)
- THE VALUE OF A PREDICTIVE DIAGNOSTIC BLOOD TEST IN MULTIPLE SCLEROSIS (MS). VALUE HEALTH, Vol. 13(3) (pp A137-A137)
- COMPARING THE TIME TRADEOFF (TTO), THE VISUAL ANALOGUE SCALE (VAS) AND THE EQ-5D VALUE-SETS IN PATIENTS TREATED WITH PAINFUL DIABETIC PERIPHERAL NEUROPATHY (PDPN) OR POST-HERPETIC NEURALGIA (PHN). VALUE HEALTH, Vol. 13(3) (pp A212-A212)
- ASSOCIATION BETWEEN SELF-REPORTED NEUROPATHIC PAIN SEVERITY AND THE EQ-5D IN PATIENTS WITH PAINFUL DIABETIC PERIPHERAL NEUROPATHY (PDPN) OR POST-HERPETIC NEURALGIA (PHN). VALUE HEALTH, Vol. 13(3) (pp A213-A213)
- ASSESSING THE IMPACT OF PAINFUL DIABETIC PERIPHERAL NEUROPATHY (PDPN) OR POST-HERPETIC NEURALGIA (PHN) RELATED HEALTH IMPAIRMENT ON LOSS OF PRODUCTIVE TIME (LOPT). VALUE HEALTH, Vol. 13(3) (pp A61-A61)
- MAINTENANCE OF PHYSICAL FUNCTION IMPROVES EMPLOYMENT STATUS OVER TIME FOR PATIENTS WITH EARLY RHEUMATOID ARTHRITIS. RHEUMATOLOGY, Vol. 49 (pp I72-I73)
- Economic Evaluation of Zoledronic Acid for the Prevention of Osteoporotic Fractures in Post-Menopausal Women with Early Breast Cancer Receiving Aromatase Inhibitors in the United Kingdom. CANCER RESEARCH, Vol. 69(24) (pp 574S-574S)
- COST-EFFECTIVENESS OF ATORVASTATIN IN ACUTE CORONARY SYNDROME PATIENTS IN THE NETHERLANDS. VALUE HEALTH, Vol. 12(7) (pp A335-A335)
- HANDLING UNCERTAINTY IN THE CASE OF COMBINED END-POINTS. VALUE HEALTH, Vol. 12(7) (pp A235-A235)
- COMPARISON OF THREE META-MODELS FOR UNCERTAINTY ANALYSIS. VALUE HEALTH, Vol. 12(7) (pp A235-A235)
- THE VALUE OF ADDED LIFE YEARS AS A FUNCTION OF AGE, PROGNOSIS AND QUALITY OF LIFE. VALUE HEALTH, Vol. 12(3) (pp A4-A5)
- THE POWER OF ASSUMPTIONS. VALUE HEALTH, Vol. 12(3) (pp A34-A34)
- Cost-effectiveness of atazanavir compared to lopinavir in treatment-naive HIV-1 patients in Scotland. HIV MED, Vol. 10 (pp 41-42)
- ASSESSING ANTIMICROBIAL SUCCESS RATES IN THE TREATMENT OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) COMPLICATED SKIN AND SOFT TISSUE INFECTIONS (CSSTI): A BAYESIAN META-ANALYSIS. VALUE HEALTH, Vol. 11(6) (pp A428-A428)
- COST-EFFECTIVENESS ANALYSIS OF CASPOFUNGIN VERSUS AMPHOTERICIN B, VORICONAZOLE, AND ANIDULAFUNGIN IN THE TREATMENT OF INVASIVE CANDIDIASIS. VALUE HEALTH, Vol. 11(6) (pp A437-A437)
- ESTIMATING THE QUALITY OF LIFE IMPACTS OF TOLTERODINE AND TAMSULOSIN TREATMENT IN MEN WITH LOWER URINARY TRACT SYMPTOMS AND OVERACTIVE BLADDER. VALUE HEALTH, Vol. 11(6) (pp A655-A655)
- COST EFFECTIVENESS ANALYSIS OF REYATAZ (R) VERSUS KALETRA (R) IN THE TREATMENT OF NAIVE HIV PATIENTS IN ITALY. VALUE HEALTH, Vol. 11(6) (pp A351-A351)
- COST EFFECTIVENESS OF HIGH DOSE ATORVASTATIN IN ACUTE CORONARY SYNDROME PATIENTS IN THE UK. VALUE HEALTH, Vol. 11(6) (pp A405-A405)
- A BAYESIAN META-ANALYSIS OF THE EFFICACY OF SIX ANTIMICROBIAL AGENTS FOR CONFIRMED STAPHYLOCOCCUS AUREUS COMPLICATED SKIN AND SOFT-TISSUE INFECTIONS (CSSTIS). VALUE HEALTH, Vol. 11(6) (pp A428-A428)
- A pharmacoeconomic analysis of schizophrenic patients switching from branded to generic risperidone involving a possible compliance loss. VALUE HEALTH, Vol. 11(3) (pp A118-A118)
- Efficacy of recombinant activated factor VII (rFVlla) vs. activated prothrombin complex concentrate (APCC) in patients with hemophilia with inhibitors: A Bayesian meta-analysis. BLOOD, Vol. 110(11) (pp 59B-59B)
- Dealing with competing causes of death, illness and costs: The Disease Elimination Life Table Analysis (DELTA) model. VALUE HEALTH, Vol. 10(6) (pp A454-A454)
- A pharmacoeconomic analysis of compliance gains on antipsychotic medications. VALUE HEALTH, Vol. 10(6) (pp A294-A294)
- The cost effectiveness of paliperidone extended-release OROS in Sweden, Finland, Denmark and Norway. VALUE HEALTH, Vol. 10(6) (pp A294-A295)
- Spatial interpolation. VALUE HEALTH, Vol. 10(6) (pp A453-A453)
- Recombinant activated factor VII (RFVIIA)vs. activated prothrombin complex concentrate (APCC) for on-demand treatment of joint bleeds in hemophiliacs with inhibitors: A systematic review and Bayesian meta-regression survival model with time-dependent covariates. VALUE HEALTH, Vol. 10(6) (pp A284-A285)
- The cost-effectiveness of risperidone long-acting injectable in Sweden. VALUE HEALTH, Vol. 10(6) (pp A293-A294)
- Costs and effects of HBV-NAT screening in the Netherlands. TRANSFUSION, Vol. 47(3) (pp 266A-266A)
- The fate of blood components: Distributions of patients to whom they are transfused, their age and diagnoses. TRANSFUSION, Vol. 47(3) (pp 268A-269A)
- Cost-effectiveness of zoledronic acid in the prevention of fractures in postmenopausal women with early breast cancer receiving aromatase inhibitor: Application to the United Kingdom. EJC SUPPLEMENTS, Vol. 5(4) (pp 156-156)
- Ten years of blood transfusions: Use, disease and survival. TRANSFUSION, Vol. 46(9) (pp 153A-154A)
- Ten years of blood transufsions: Use, disease and survival. VOX SANG, Vol. 91 (pp 319-319)
- Cost effectiveness of adalimumab therapy vs. conventional care in the United Kingdom (UK) patients with active ankylosing spondylitis (AS). ANNALS OF THE RHEUMATIC DISEASES, Vol. 65 (pp 207-208)
- All proton pump inhibitors are equivalent for treatment of GERD. CLEV CLIN J MED, Vol. 72(12) (pp 1100-1100)
- Cost effectiveness of fondaparinux compared with enoxaparin for extended prophylaxis against venous thromboembolism in patients undergoing hip fracture surgery using Dutch estimates of costs. VALUE HEALTH, Vol. 8(6) (pp A116-A116)
- Cost effectiveness of extended prophylaxis with fondaparinux to prevent venous thromboembolism in patients undergoing hip fracture surgery using UK and Dutch estimates of costs. VALUE HEALTH, Vol. 8(6) (pp A116-A116)
- A discrete event simulation (DES) model to describe schizophrenia. VALUE HEALTH, Vol. 8(6) (pp A207-A207)
- Cost-effectiveness of PCI with or without drug-eluting stents vs. bypass surgery for treatment of multivessel coronary disease: 1-year results from the ARTS I and ARTS II trials. CIRCULATION, Vol. 112(17) (pp U612-U612)
- Costs and effects of Risperdal Consta (TM) in comparison to conventional depot and shortacting atypical formulations in Portugal. VALUE HEALTH, Vol. 7(6) (pp 778-778)
- The costs and effects of clopidogrel in comparison to ASA or placebo for several patient populations in Denmark. VALUE HEALTH, Vol. 7(6) (pp 642-642)
- VIOLATIONS OF THE ADDITIVE ASSUMPTION IN THE STANDARD QALY APPROACH: EXTRA-MAXIMAL TRADE OFFS. QUALITY OF LIFE RESEARCH, Vol. 13(9) (pp 1570-1570)
- MODELING TIME TRADE OFF VALUATIONS: IN SEARCH OF A GOOD FIT. QUALITY OF LIFE RESEARCH, Vol. 13(9) (pp 1499-1499)
- Costs and effects of risperdal Consta (TM) in comparison to conventional depot and short-acting atypical formulations in Germany. VALUE HEALTH, Vol. 6(6) (pp 692-692)
- Cost-effectiveness analysis of clopidogrel in acute coronary syndromes without ST-segment elevation in the Netherlands. VALUE HEALTH, Vol. 6(6) (pp 667-668)
- Efficacy of treatment of hypertension: A meta-analysis of 68,000 patients and its implications for current practice. JOURNAL OF HYPERTENSION, Vol. 21 (pp S115-S115)
- Cost-effectiveness of prehospital thrombolysis. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, Vol. 41(6) (pp 524A-524A)
- The costs of severe sepsis - The Netherlands, 2000. VALUE HEALTH, Vol. 5(6) (pp 561-561)
- Incidence of severe sepsis in the Netherlands: A point prevalence survey. VALUE HEALTH, Vol. 5(6) (pp 576-576)
- A discrete events model of long-term outcomes and cost of treatment with long acting risperidone in schizophrenia. VALUE HEALTH, Vol. 5(6) (pp 515-516)
- Simulating the course of schizophrenia using discrete events modelling. VALUE HEALTH, Vol. 5(6) (pp 524-524)
- Working status after CABG and stented angioplasty: results from the ARTS study. EUROPEAN HEART JOURNAL, Vol. 23 (pp 260-260)
- Cost-effectiveness of the sirolimus eluting Bx-VELOCITY stent: 1-year results. EUROPEAN HEART JOURNAL, Vol. 23 (pp 691-691)
- Cost-effectiveness of drotrecogin alfa (activated) (Xigris (TM)) in severe sepsis. CRIT CARE MED, Vol. 30(2) (pp 493-493)
- Increased survivorship with drotrecogin alfa (activated) in the treatment of severe sepsis: The effect on hospital costs. CRIT CARE MED, Vol. 29(12) (pp A1-A1)
- Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: Insights from the arterial revascularization therapy study (ARTS) trial.. AM J CARDIOL, Vol. 88(5A) (pp 4G-4G)
- Stenting is less expensive than bypass surgery for multivessel coronary disease but is associated with repeat revascularization. Evidence-based Cardiovascular Medicine, Vol. 5(3) (pp 94-95)
- Comparison of effectiveness and cost effectiveness of CABG versus percutaneous intervention in diabetic patients with multivessel disease. CIRCULATION, Vol. 102(18) (pp 550-550)
- Comparison of effectiveness and cost effectiveness of CABG versus percutaneous intervention in patients with multi-vessel disease assessed by age. EUR HEART J, Vol. 21 (pp 478-478)
- Quality of life after CABG and stented angioplasty: results from the ARTS study. EUR HEART J, Vol. 21 (pp 221-221)
- Debate II: A randomized comparison of cost-effectiveness of primary versus provisional stenting. CIRCULATION, Vol. 100(18) (pp 790-791)
- Cost-effectiveness analysis of national clinical guidelines. DIABETES, Vol. 48 (pp A416-A416)
- Arterial revascularisation therapy study: The ARTS study, a randomised trial of bypass-surgery versus stenting in multivessel coronary disease.. CIRCULATION, Vol. 98(17) (pp 498-498)
- Cost effectiveness of abciximab in patients with unstable angina according to the troponin T status. CIRCULATION, Vol. 98(17) (pp 358-359)
- Assessing the probability of economic dominance without data from a head to head trial. MED DECIS MAKING, Vol. 18(4) (pp 489-489)
- Costs and effects in therapy for acute coronary syndromes: The case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. EUROPEAN HEART JOURNAL, Vol. 19 (pp D59-D66)
- Costs and effects of stent implantation versus balloon angioplasty. J AM COLL CARDIOL, Vol. 31(2) (pp 50A-50A)
- Cost-effectiveness of hip fracture prevention: The later the better?. J BONE MINER RES, Vol. 12 (pp F558-F558)
Reports
- Valuing health-related quality of life: An EQ-5D-5L value set for England
- Examining productivity losses associated with health related quality of life using patient and general population data. View this article in WRRO
- Case-mix methodology for the NHS outcomes framework GP Patient Survey Questionnaire Data View this article in WRRO
Posters
- P60 A New Online Tool for Valuing Health States: Eliciting Personal Utility Functions for the EQ-5D-5L.
Working papers
- Valuing health-related quality of life: An EQ-5D-5L value set for England. Health Economics (United Kingdom), 27, 7-22. View this article in WRRO
Other
- Correction to: An Innovative Approach to Modelling the Optimal Treatment Sequence for Patients with Relapsing–Remitting Multiple Sclerosis: Implementation, Validation, and Impact of the Decision-Making Approach. Advances in Therapy, 39(2), 909-909.
Preprints
- Health Preferences in Childhood Autism Spectrum Disorder (ASD): A Discrete Choice Experiment using the Childhood Autism Rating Scale (CARS2), Research Square Platform LLC.
- Feasibility Assessment of a Health Preference Study in Autism Based on the Childhood Autism Rating Scale (CARS2): A Qualitative Study with Clinicians and Caregivers, Research Square Platform LLC.
- A Comparison of Alternative Variants of the Lead and Lag Time TTO.
- Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States. Clinical Cardiology, 39(6), 313-320. View this article in WRRO